{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:07:00Z","timestamp":1777878420287,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LZ23H080002"],"award-info":[{"award-number":["LZ23H080002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules on the surface of malignant plasma cells and CD3 on the surface of T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Addressing the issue of improving the prognosis of triple-class refractory MM patients has become a significant clinical challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This is a brief report.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This article summarizes the latest updates of BsAbs treatment of MM from the 2022 ASH annual meeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>BsAbs that target B-cell maturation antigen and G protein-coupled receptor family C group 5 memberD have demonstrated remarkable clinical activity and favorable safety profiles. Many potential targets for myeloma cells are currently undergoing phase I\/II clinical trials, and these off-the-shelf bispecific molecules are likely to become a critical part of the MM treatment landscape.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This article provides an overview of the latest advances in BsAbs immunotherapy for refractory and relapsed MM and highlights significant findings from the 2022 ASH annual meeting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406223231213251","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:46:29Z","timestamp":1700279189000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting"],"prefix":"10.1177","volume":"14","author":[{"given":"Xuejiao","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Zhejiang University Cancer Center, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianai","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Zhejiang University Cancer Center, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou 310003, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou 310003, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4575-3287","authenticated-orcid":false,"given":"Liangshun","family":"You","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou 310003, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"key":"bibr1-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158801"},{"key":"bibr2-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159711"},{"key":"bibr3-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159756"},{"key":"bibr4-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166494"},{"key":"bibr5-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440"},{"key":"bibr6-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162738"},{"key":"bibr7-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169971"},{"key":"bibr8-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159969"},{"key":"bibr9-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158396"},{"key":"bibr10-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157713"},{"key":"bibr11-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167008"},{"key":"bibr12-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157977"},{"key":"bibr13-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157988"},{"key":"bibr14-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157485"},{"key":"bibr15-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159707"},{"key":"bibr16-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162555"},{"key":"bibr17-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157525"},{"key":"bibr18-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159205"},{"key":"bibr19-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157585"},{"key":"bibr20-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159353"},{"key":"bibr21-20406223231213251","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169072"}],"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223231213251","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223231213251","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223231213251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:19:51Z","timestamp":1777591191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223231213251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":21,"alternative-id":["10.1177\/20406223231213251"],"URL":"https:\/\/doi.org\/10.1177\/20406223231213251","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"20406223231213251"}}